YOLFTbeta
JETEMA Co. Ltd

JETEMA Co. Ltd

216080 · KQ · Healthcare / Medical Instruments & Supplies

6,060.00KRW-100.00 (-1.62%)

Price History

Full chart

Market Stats

Previous Close6,160.00
Open6,100.00
Day Range6,030.00 – 6,250.00
52-Week Range3,800.00 – 11,280.00
Volume44.31K
Market Cap224.47B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.66
50-Day Avg5,482.90
200-Day Avg6,632.18

About

JETEMA, Co., Ltd., a bio venture company, engages in the research and development of medicines and medical devices. It offers clostridium botulinum toxins, fillers, lifting threads for medical treatment, elastin and collagen stimulate solution under Ecolla, and healthy skin care under vitten brand names. The company also provides skin care hyaluronic acid masks. JETEMA, Co., Ltd. was founded in 2009 and is headquartered in Wonju-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOJeong Sun Nam
  • Employees265
  • Headquarters1283-4, Gagok-ri, Wonju-si, South Korea, Korea
  • Websitehttps://www.jetema.com

Leadership

  • Jeong Sun NamChief Executive Officer
  • Jae Young KimChief Executive Officer

Financials

Income Statement

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue8.17B11.21B13.30B20.66B33.22B45.99B58.72B68.52B76.90B
Growth (%)-+37.17%+18.67%+55.33%+60.81%+38.44%+27.66%+16.70%+12.23%
Cost of Revenue5.46B5.86B7.17B11.86B18.15B23.71B30.42B35.12B40.06B
Gross Profit2.71B5.35B6.13B8.80B15.07B22.29B28.30B33.40B36.84B
Gross Margin33.20%47.71%46.07%42.60%45.36%48.46%48.19%48.75%47.90%
Operating Expense6.72B9.90B16.87B14.38B12.79B23.60B29.04B33.52B33.02B
Operating Income-4.00B-4.55B-10.74B-5.58B2.28B-1.31B-745.93M-118.90M3.82B
Operating Margin-49.02%-40.61%-80.77%-27.00%6.86%-2.85%-1.27%-0.17%4.97%
EBITDA-----16.58B22.31B15.48B11.45B
EBITDA Margin-----36.04%37.99%22.59%14.89%
Net Income-5.56B-15.70B-14.72B-9.33B10.88B1.46B13.97B-188.25M-6.60B
Net Income Margin-68.11%-140.11%-110.71%-45.15%32.76%3.16%23.79%-0.27%-8.59%
R&D--6.85B5.05B3.91B6.26B10.22B9.81B10.03B
R&D as % of Total Revenue--51.53%24.46%11.77%13.62%17.41%14.32%13.04%
Interest Expense000616.73M3.68B9.58B12.88B12.05B10.58B
Interest Expense % of Total Revenue0.00%0.00%0.00%2.99%11.08%20.83%21.93%17.59%13.76%

Balance Sheet

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets18.97B51.29B62.29B66.86B147.93B188.35B244.23B222.72B209.14B
Total Liabilities15.18B56.33B28.35B25.30B93.36B131.41B171.17B151.29B144.13B
Total Equity3.79B-5.04B33.94B41.56B54.56B56.95B71.51B72.28B65.46B
Cash1.93M14.01B3.03B16.94B75.20B76.59K46.22B23.10B4.89B
Total Debt5.48B14.41B13.42B14.47B-----
Net Debt--11.11B--85.94B82.21B94.52B111.52B

Cash Flow

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.58B-5.93B-8.11B1.57B6.16B14.18B6.88B3.72B11.05B
Investing Cash Flow-9.74B-21.41B-15.58B9.46B-17.40B-107.29B-8.11B-10.57B-
Financing Cash Flow5.64B32.66B20.66B3.67B68.78B38.15B26.38B-17.91B-
Capital Expenditure8.72B12.68B12.85B3.08B16.27B63.99B7.21B8.79B15.85B
Free Cash Flow----1.65B-10.11B-49.82B-327.69M-5.08B-4.80B
FCF to OCF----105.47%-164.20%-351.40%-4.76%-136.60%-43.42%

Earnings

Report DateMar 30, 2020May 14, 2020Aug 14, 2020Nov 16, 2020Jan 29, 2021Apr 29, 2021Aug 16, 2021Nov 15, 2021Jan 24, 2022May 13, 2022Aug 12, 2022Nov 14, 2022Feb 9, 2023Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------------
EPS Actual-312.4342.50-263.00-122.009.6477.4320.79-146.00619.71199.0098.0015.00-1106.39-45.94-170.24-100.57707.16-39.37-0.90-91.53126.29-102.20-59.81-85.7763.33-58.2942.83
Surprise---------------------------
TimingAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-market--------------

Key Statistics & Ratios

Market Cap224.47B
Enterprise Value363.42B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.93
Price / Book3.28
Revenue (TTM)76.58B
Gross Profit (TTM)37.11B
EBITDA12.26B
Profit Margin-1.74%
Operating Margin11.48%
Return on Equity-2.64%
Return on Assets1.00%
Shares Outstanding37.29M
Shares Float26.41M
Beta0.66
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jan 3, 20252:1
  • Jun 25, 20202:1